JAMA Network
About The Study: The findings of this study of women in Denmark followed up from age 45 suggest that systemically administered (oral or transdermal) hormonal therapy before and during menopause is associated with higher risk of depression, especially in the years immediately after initiation, whereas locally administered (intravaginal or intrauterine) hormonal therapy is associated with lower risk of depression for women 54 years or older.
Authors: Merete Osler, M.D., Ph.D., D.M.Sc., of the Bispebjerg and Frederiksberg Hospitals in Frederiksberg, Denmark, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.39491)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
